The full potential of the immune system for personalized cancer treatment.

Elisa Abate*

Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy

Introduction

The human immune system, a complex network of cells, tissues, and biochemicals they produce, defends the body against viruses, bacteria, and other invaders. However, cancer often finds ways to hide from the immune system or block its ability to fight. In recent years, the field of oncology has seen a paradigm shift towards harnessing the power of the immune system to combat cancer. This approach, known as immunotherapy, has shown promising results in treating various types of cancer. The next frontier in this field is personalized cancer treatment, tailoring immunotherapies to individual patients based on their unique genetic and immunological profile [1].

- The immune system plays a dual role in cancer. On the one hand, it can detect and eliminate cancer cells, a process known as immune surveillance. On the other hand, certain immune responses can promote cancer growth and progression. Understanding this dichotomy is crucial for developing effective immunotherapies.
- Immunotherapy represents a new pillar of cancer treatment, alongside surgery, chemotherapy, and radiation therapy. It works by enhancing the immune system's ability to fight cancer. There are several types of immunotherapies, including immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines.
- While immunotherapies have revolutionized cancer treatment, they don't work for everyone. This is where personalized cancer treatment comes in. By understanding a patient's unique genetic makeup and immune response, doctors can tailor treatments to increase their effectiveness and reduce side effects.
- The future of personalized cancer immunotherapy is bright. Advances in genomics, proteomics, and immunology are paving the way for more precise and effective treatments. However, several challenges need to be addressed, including the high cost of personalized therapies and the need for better predictive biomarkers [2].

Personalizing Immunotherapy: The Role of Biomarkers

The effectiveness of immunotherapy can vary greatly among patients due to differences in individual immune responses and tumor characteristics. This is where biomarkers come in. Biomarkers are biological molecules found in blood, other body fluids, or tissues that signal normal or abnormal processes, conditions, or diseases. In the context of cancer immunotherapy, biomarkers can help predict who will respond to treatment [3].

For example, the presence of the PD-L1 protein on cancer cells has been associated with better responses to PD-1/PD-L1 inhibitors. Similarly, a high mutational burden (i.e., a high number of mutations within tumor cells) can make a cancer more likely to respond to immunotherapy because it may produce more neoantigens, which are potential targets for the immune system [4].

Challenges and future directions

Despite the promise of personalized cancer immunotherapy, several challenges remain. These include the high cost of developing and administering personalized treatments, the need for more reliable and accessible biomarkers, and the management of immune-related side effects. Nevertheless, the future of personalized cancer immunotherapy is bright. Advances in technologies such as next-generation sequencing and artificial intelligence are enabling more precise characterization of tumors and immune responses. This, in turn, is paving the way for more effective and personalized immunotherapies.

The full potential of the immune system for personalized cancer treatment is vast. As we continue to deepen our understanding of the intricate interplay between the immune system and cancer, we move closer to a future where every cancer patient has a personalized treatment plan that offers them the best chance of survival. The full potential of the immune system for personalized cancer treatment is yet to be realized. However, the progress made so far is encouraging. As we continue to unravel the complexities of the immune system and cancer, we move closer to a future where every cancer patient has a personalized treatment plan that gives them the best chance of survival [5].

References

1. Jiang T, Shi T, Zhang H, et al. Tumor neoantigens: From basic research to clinical applications. J Hematol Oncol. 2019;12:1-3.
2. Yang W, Lee KW, Srivastava RM, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature Med. 2019;25(5):767-75.

***Correspondence to:** Elisa Abate, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy, E-mail:- elisa.a@unicampania.it

***Received:** 01-Jul-2023, Manuscript No. AAAJMR-23-105802; **Editor assigned:** 04-Jul-2022, PreQC No. AAAJMR-23-105802(PQ); **Reviewed:** 18-Jul-2023, QC No. AAAJMR-23-105802; **Revised:** 21-Jul-2023, Manuscript No. AAAJMR-23-105802(R); **Published:** 28-Jul-2023, DOI:10.35841/aaajmr-7.4.184*

***Citation:** Abate E. The full potential of the immune system for personalized cancer treatment. Allied J Med Res. 2023;7(4):184*

3. Tzeng SY, Patel KK, Wilson DR, et al. *In situ* genetic engineering of tumors for long-lasting and systemic immunotherapy. Proc Natl Acad Sci. 2020;117(8):4043-52.
4. Francis DM, Thomas SN. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Adv Drug Deliv Rev. 2017;114:33-42.
5. Xu C, Nam J, Hong H, et al. Positron emission tomography-guided photodynamic therapy with biodegradable mesoporous silica nanoparticles for personalized cancer immunotherapy. ACS Nano. 2019;13(10):12148-61.

Citation: *Abate E. The full potential of the immune system for personalized cancer treatment. Allied J Med Res. 2023;7(4):184*